What’s 340B? An economist’s view of the recent wave of 340B litigation
But this change has led to complex relationships among pharmaceutical manufacturers, hospitals, pharmacies, and third-party administrators, increasing scrutiny...
This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
CRA combines in-depth industry knowledge and cutting-edge analytics to evaluate issues being litigated and debated in the healthcare sector. Our industry knowledge enables us to explain, for example, the nuances of provider reimbursement or the patient incentives created by high deductible health insurance plans, and our economic, statistical, accounting, investigative, and finance skills—as well as our familiarity with key healthcare datasets—equips CRA to provide rigorous, defensible analyses tailored to the specific facts of a litigation or regulatory dispute.
Our experts have broad and deep experience in the healthcare sector including hospitals, physician practices, health insurance and health benefit plans, ACOs, PBMs, wholesalers, pharmacies, pharmaceuticals and biologicals, medical devices, clinical laboratories, dialysis facilities, ambulance transport, nursing homes, and home healthcare.
But this change has led to complex relationships among pharmaceutical manufacturers, hospitals, pharmacies, and third-party administrators, increasing scrutiny...
The Federal Trade Commission (FTC), Department of Justice (DOJ), and state regulators have publicly stated that non-compete agreements (NCAs) are an...
CRA is a proud sponsor of the event. This year’s Symposium program, entitled “Policy to Practice: Federal Healthcare Reform at the State Level,” explores how...
Zack Cooper is a panelist during the session titled “Academic Perspectives on Healthcare Competition.” Academic researchers have played a pivotal role in...
